American Healthcare REIT Delivers Strong Q2: Revenue Climbs 24%, Acquisition Pipeline Tops $1B
AHR sits 44% above its 52-week low of $39.305.
Summary
Q2 2026 results for American Healthcare REIT feature 24% revenue growth to $674M and net income of $31M, driven by acquisitions and higher occupancy. A $1.04B post-quarter acquisition and a new $1.35B credit facility were also announced.
Key Events · Earnings and Guidance · AHR
-
Q2 Revenue Surges 24%
Total revenues reached $674.25 million, up from $542.50 million in Q2 2025, driven by higher resident fees and services across ISHC and SHOP segments.
-
Net Income Swings to $31M
Net income attributable to controlling interest was $30.6 million ($0.16 per share), compared to $9.9 million a year ago, reflecting improved operating leverage.
-
$1.04B Post-Quarter Acquisition
Subsequent to June 30, 2026, the company acquired 11 senior housing properties for an aggregate contract purchase price of $1.041 billion, expanding its SHOP portfolio.
-
New $1.35B Credit Facility
On April 1, 2026, the company replaced its prior credit facility with a new $1.35 billion facility, increasing revolving capacity to $800 million and extending maturity to 2030.
Analysis · AHR · Real Estate & Construction
A robust second quarter saw revenue climb 24% year-over-year to $674 million, while net income reached $31 million, fueled by higher occupancy and recent acquisitions. Nearly $290 million was deployed in acquisitions during the first half, and an additional $1.04 billion was committed post-quarter, underscoring an aggressive portfolio expansion. Liquidity is well supported by a new $1.35 billion credit facility, and the settlement of ATM forward agreements added $229 million in equity proceeds. Leadership has been consolidated under Jeffrey T. Hanson, who now holds both Chairman and CEO roles following the prior CEO's retirement.
At the time of this filing, AHR was trading at $56.74 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $11.8B. The 52-week trading range was $39.31 to $58.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.